Medicines Patent Pool
Governance Board Meeting #35

May 15th – 16th, 2023
Hybrid meeting

Attendees

**Governance Board Members:**
Marie-Paule Kieny (Chair), Mojisola Christianah Adeyeye, Patrizia Carlevaro, Peter Maybarduk, John-Arne Røttingen, Maximiliano Santa Cruz, Pushpa Vijayaraghavan.

**Excused Board Members:**
Alexandra Volgina

**Non-voting members:**

**Medicines Patent Pool Foundation Management Team:**
Summary of Decisions

The Governance Board of the Medicines Patent Pool:

1. Requested that the Management draft a comprehensive agreement between WHO and MPP, which outlines their respective roles and responsibilities within the context of the mRNA Technology Transfer (TT) Programme. This agreement should be presented at the next Board meeting, and it was suggested that this could include a paragraph stating that other forms of collaboration may be explored in the future, subject to further discussions between the two organisations.

2. Agreed that going forward the process of approving any C-TAP licence should be as follows: the Technical Advisory Group (TAG) will conduct a first review and these findings will be shared with the Expert Advisory Group (EAG) in the form of a report from WHO. The EAG will consider the recommendations provided by WHO during a second 'light review' and will submit a report to the MPP Board.

3. Approved the 2022 financial statements and the auditors’ report.

4. Approved the Operational KPI Framework 2022 Results Report.

5. Approved all the changes resulting from the Management review of the risk register. In the specific case of Risk 7: MPP does not secure funding to implement its strategy, the Board agreed to keep this risk with a low rating [2] instead of removing it.

6. Approved the recruitment, according to the proposed timelines, of the Generic Industry, Environmental, social, and governance (ESG) Investor, and Treasurer profiles.

7. Invited Maximiliano Santa Cruz to serve for a second 3-year term until 14 October 2026.

8. Agreed to extend Alexandra Volgina’s term of office for six months, until 30 December 2023, with the caveat that her term can be further extended until 30 June 2026 if, by the end of the 6 months, she is ready to fully resume her duties as Board Member.

9. Approved the changes to the Chart of Authorities presented by the Management with the following amendments:
   - As the travel and expenses policy is often the focus of donor scrutiny, any changes should be proposed by the ED, reviewed and recommended by the FMC, and approved by the Board.
   - The Board, through the GC, shall be kept informed about the appointment of new members of the Scientific Advisory Panel (SAP), the Community Advisory Panel (CAP) and the Scientific Advisory Committee of the mRNA TT Programme (mSAC) as well as about any changes to the SAP, CAP and mSAC’s terms of reference. Updates can be provided in the GC pre-rads or by email.
10. Agreed that from now on the Spring Board meeting will be held in-person, while the Autumn meeting will be conducted virtually. The former would be longer (two full days rather than one and a half), allowing for more comprehensive strategic discussions. The latter could span three days with each day being shorter to accommodate the time differences among Board members. Furthermore, it is requested that the Spring Board meeting should take place immediately before or after the World Health Assembly (WHA).

11. Agreed that the Chair of the EAG shall continue providing an annual report on the work of the EAG during the Autumn Board meeting, soon after the EAG annual meeting is held.

12. Unanimously nominated Agnese Tonnina, MPP Grants and Operations Manager, as Secretary of the MPP Governance Board meetings.

13. Unanimously invited Marie-Paule Kieny to continue serving as the Chair of the Board until 31 August 2026, in alignment with the duration of her recently renewed terms of office. It further expressed gratitude for Marie-Paule’s commitment, dedication, and inspiring leadership as Chair of the MPP, recognising her valuable contribution to the mission of the organisation.

14. Requested the Management to amend the By-Laws to extend the duration of the Chair’s term of office to three years or such other term as may be appropriate, to align with the duration of the Board members’ terms of office.

15. Agreed that it would be beneficial to have a vice-chair who could step in when the Chair is unable to preside over a discussion and requested the Management to present a proposal for a vice-chair to the GC and the Board.